This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lampe, J. W. Articles by Potter, J. D. Search for Related Content PubMed PubMed Citation Articles by Lampe, J. W. Articles by Potter, J. D.

Prevalence of Polymorphisms in the Human UDP-Glucuronosyltransferase 2B Family: UGT2B4(D⁴⁵⁸E), UGT2B7(H²⁶⁸Y), and UGT2B15(D⁸⁵Y)¹

Cancer Prevention Research Program, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109-1024

	Abstract

Top Abstract Introduction Materials and Methods Results Discussion References

 
UDP-glucuronosyltransferases (UGTs) of the UGT2B family conjugate steroid hormones as well as bile acids and xenobiotics. UGT2Bs are expressed in numerous human tissues, such as skin, breast, prostate, adipose, and intestine and are hypothesized to modulate steroid metabolism and excretion. Polymorphisms have been identified that may modify substrate specificities or enzyme activities of UGT2B family isozymes. We determined the prevalence of the UGT2B4(D⁴⁵⁸E), UGT2B7(H²⁶⁸Y), and UGT2B15(D⁸⁵Y) polymorphisms in a sample of 233 individuals. The allele frequencies were significantly different (P < 0.02) between individuals of Caucasian and Asian descent for all three polymorphisms. In Asians (n = 32), the frequencies of the UGT2B4(D⁴⁵⁸), UGT2B7(H²⁶⁸), and UGT2B15(D⁸⁵) alleles were 1.00, 0.73, and 0.64, respectively, whereas, in Caucasians (n = 202), the frequencies of UGT2B4(D⁴⁵⁸), UGT2B7(H²⁶⁸), and UGT2B15(D⁸⁵) were 0.75, 0.46, and 0.45, respectively. The distribution of the UGT2B4(D⁴⁵⁸E), UGT2B7(H²⁶⁸Y), and UGT2B15(D⁸⁵Y) genotypes also differed by ethnic group (P < 0.0001, P = 0.002, and P = 0.02, respectively). All Asians were homozygous for UGT2B4(D⁴⁵⁸) and had a greater than 2-fold higher prevalence of the UGT2B7(H²⁶⁸) and UGT2B15(D⁸⁵) homozygous genotypes compared with Caucasians: 56.2% versus 21.8%, and 46.9% versus 22.3%, respectively. Concomitantly, only 9.4% of Asians were UGT2B7(Y²⁶⁸) homozygous and 18.7% were UGT2B15(Y⁸⁵) homozygous compared with 29.2% and 32.2%, respectively, of Caucasians. The data suggest that there may be large differences in UGT2B polymorphisms between Asians and Caucasians. This warrants evaluation both in larger, multiethnic cohorts and in relation to known ecological differences in risk of sex hormone-dependent cancers.

	Introduction

Top Abstract Introduction Materials and Methods Results Discussion References

 
In humans, two families of UGTs³ catalyze the transfer of the glucuronyl group from uridine 5'-disphosphoglucuronic acid to endogenous molecules, such as bile acids, steroids, and thyroid hormones, and a wide range of exogenous substrates. Generally, the UGT1 family catalyzes the glucuronidation of bilirubin and xenobiotic phenols as well as some steroids (1) . The UGT2 family includes the subfamilies 2A and 2B; the 2B enzymes glucuronidate primarily steroids (2) . UGTs play an important role in detoxification and chemoprotection (3) , as well as drug metabolism and regulation of steroid hormone levels (2 , 4) . Polymorphisms in the UGTs are postulated to contribute to interindividual variation in drug disposition (5) and certain UGT1A variants are known to be associated with altered bilirubin excretion (6) . It is highly likely that certain UGT polymorphisms may also influence steroid hormone metabolism and cancer susceptibility; however, the relationship between genetic variation in glucuronidation and cancer risk has yet to be explored.

Polymorphisms have been identified in at least three of the human UGT2B genes: UGT2B4, UGT2B7, and UGT2B15 (7, 8, 9) . Reported nucleotide sequence differences in UGT2B4 lead to amino acid changes at positions 109, 396, and 458. The variant UGT2B4(L^109,396D⁴⁵⁸), isolated from human liver, has leucine (L), instead of phenylalanine (F) residues at amino acids 109 and 396 (7 , 10) . A difference of two nucleotides also leads to another single amino acid change of aspartate (D) to glutamate (E) at position 458 (7) . UGT2B4 is primarily involved in the conjugation of catechol estrogens, bile acids (specifically hyodeoxycholic acid), and certain exogenous phytochemicals (7) . Both UGT2B4(D⁴⁵⁸) and (E⁴⁵⁸) are expressed in liver and a wide range of extrahepatic tissues, including those that are targets for steroid hormones; however, there is no apparent difference in substrate specificity between the two forms (7) . Lévesque et al. (7) reported that in a sample of 26 Caucasian individuals, the frequency of the variant E⁴⁵⁸ allele was 0.385. The authors did not detect the presence of the UGT2B4(L^109,396D⁴⁵⁸) variant in any of the tissues or genomic DNA sampled; however, they suggested that this may be a rare allele not found in their sample population.

In UGT2B7, there is an amino acid change from histidine (H) to tyrosine (Y) at amino acid 268 (8) , the proposed location of the substrate-binding site (11) . The prevalence of the two alleles and a corresponding phenotypic difference have not been determined. UGT2B7 glucuronidates 4-hydroxycatechol estrogens (12) and mono- and dihydroxylated androgens with a hydroxyl group in the 3, 6, and 17ß positions; however, UGT2B7 has the highest activity toward steroids containing a 3-hydroxy moiety (13 , 14) . UGT2B7 expression has been detected in liver, kidney, pancreas, brain, and the gastrointestinal tract (15, 16, 17) .

In UGT2B15, a thymine in place of a guanine leads to an amino acid change at position 85 from aspartic acid (D) to tyrosine (Y; Ref. 9 ). UGT2B15 is expressed in numerous human tissues (e.g., liver, kidney, testis, mammary gland, prostate, and lung; Ref. 9 ). This isozyme catalyzes the glucuronidation of a wide range of substrates, including simple phenolic compounds, drugs, and C₁₉ steroids, such as 5-androstane-3,17ß-diol and dihydrotestosterone, at the 17ß position (18 , 19) . Coumarins, flavonoids, and anthraquinones, phytochemicals that are present in high amounts in certain plant foods, also are glucuronidated by UGT2B15 (18) . To date, only one study has examined the prevalence of the UGT2B15 polymorphic allele; Lévesque et al. (9) determined that of a sample of 27 Caucasians, 6 (19%) were homozygous for Y⁸⁵ (Y⁸⁵/Y⁸⁵), 5 (22%) were homozygous for D⁸⁵ (D⁸⁵/D⁸⁵), and 16 (73%) had both alleles (D⁸⁵/Y⁸⁵).

The purpose of our work was to determine the prevalence of the described genetic polymorphisms in UGT2B4, UGT2B7, and UGT2B15 in a sample of individuals from the Seattle, Washington area.

	Materials and Methods

Top Abstract Introduction Materials and Methods Results Discussion References

 
Two hundred and forty-five nonsmokers, 20–40 years of age, from the Seattle area were screened for participation in a cross-sectional study of diet and biotransformation enzymes. Exclusion criteria included history of gastrointestinal disorders, weight loss or gain >4.5 kg within the past year, major changes in eating habits within the past year (e.g., adoption of a different dietary pattern), exercise regimens requiring significant short-term dietary changes, antibiotic use within the past 3 months, body weight >150% of ideal, current drug therapy for a diagnosed disease, chronic nonsteroidal anti-inflammatory drug use, alcohol intake greater than two drinks per day (two drinks being equivalent to 720 ml of beer, 240 ml of wine, or 90 ml of hard liquor), occupational exposure to smoke or organic solvents, chronic passive exposure to tobacco smoke, intake of pharmacological doses of dietary supplements, and serum alanine aminotransferase concentrations above the normal range.

All participants had venous blood samples drawn for genomic DNA collection. DNA was extracted from lymphocytes according to standard methods using a proteinase K digestion followed by phenol-chloroform extractions (20) . A demographic and health questionnaire was completed. Information requested on the questionnaire included usual diet (e.g., vegetarian, diabetic, low-fat), food preferences, alcohol intake, medical history, vitamin/mineral and herbal supplement information, usual activity, medications, environmental exposures, and ethnic/racial background. The study design was approved by the Institutional Review Board: Human Subjects Committee at the Fred Hutchinson Cancer Research Center. Informed written consent was obtained from all participants prior to the start of the study.

Determination of UGT2B4, UGT2B7, and UGT2B15 Genotypes
The UGT2B4 F¹⁰⁹L, F³⁹⁶L, and D⁴⁵⁸E; UGT2B7; and UGT2B15 genotypes were determined using an oligonucleotide ligation assay (21 , 22) . Amplification of the correct PCR fragments was confirmed by sequencing.

UGT2B4.
To distinguish the UGT2B4(D⁴⁵⁸E) (GenBank accession nos. AJ005162 and AF064200, respectively) and UGT2B4(L^109,396,D⁴⁵⁸) (GenBank accession no. AF081793) alleles, the polymorphisms at amino acids 109, 396, and 458 were determined. Three fragments were amplified by PCR using the following primers: for F¹⁰⁹L, FP1 (5'-GAGGATATTATCAAGCAGCT-3') and RP1 (5'-CAGCATCTGCAAGAACAACA-3'); for F³⁹⁶L, FP2 (5'-ACCTCATGGTGGAGCCAATG-3') and RP2 (5'-ACATTGTGTGGAAGTCCAAA-3'); and for D⁴⁵⁸E, FP3 (5'-TTCATCATGATCAACCAGTGA-3') and RP3 (5'-CTTCCAGCCTCAGACGTAAT-3'). The PCR reactions contained 10 mM Tris-HCl (pH 8.3), 50 mM KCl, 1.5 mM MgCl₂, 0.001% gelatin, 50 ng/µl BSA, 200 µM deoxynucleotide triphosphates (100 µM for F¹⁰⁹L and D⁴⁵⁸E), 150 nM amplification primers, 100 ng of genomic DNA, and 0.5 units of AmpliTaq DNA polymerase (Perkin-Elmer, Foster City, CA). The cycling conditions on a PTC-100 thermal cycler (MJ Research, Inc., Watertown, MA) were as follows: (a) for F¹⁰⁹L and F³⁹⁶L, 94°C for 5 min, followed by 30 cycles of 94°C for 30 s, 58°C for 45 s, and 72°C for 60 s and 1 cycle of 72°C for 5 min; and (b) for D⁴⁵⁸E, 94°C for 5 min, followed by 30 cycles of 94°C for 30 s, 60°C for 45 s, and 72°C for 60 s and 1 cycle of 72°C for 5 min.

The F¹⁰⁹L, F³⁹⁶L, and D⁴⁵⁸E polymorphisms were determined by oligonucleotide ligation assay using the primers listed in Table 1 . The modification for the allele-specific primers was 5'-biotin and 5'-phosphate and 3'-digoxigenin for the common primer. For the ligation, the PCR reactions were diluted with 35 µl of 0.1% Triton X-100. The ligation reactions consisted of 10 µl of diluted PCR product, and 10 µl of 40 mM Tris-HCl (pH 8.0), 20 mM MgCl₂, 25 mM KCl, 2 mM DTT, 2 mM NAD⁺, 0.1% Triton X-100, 16 fmol/µl biotinylated primer, 16 fmol/µl common primer, and 0.015 units of thermostable ligase (Epicentre Technologies, Madison, WI). The cycling conditions for the ligation were as follows: 15 cycles of 93°C for 30 s and 58°C for 2 min. The reaction was stopped with 10 µl of a buffer containing 0.1 M EDTA (pH 8.0) and 0.1% Triton X-100. The ligation reactions were then transferred into streptavidin-coated 96-well plates. After incubation at room temperature for 60 min, the plates were washed twice with 10 mM NaOH containing 0.05% Tween 20, followed by two washes with 200 µl of 100 mM Tris-HCl (pH 7.5), 150 mM NaCl, and 0.05% Tween 20. The plates were then incubated with 40 µl of a 1000-fold dilution of antidigoxigenin Fab fragment-phosphatase conjugate (0.75 units/µl; Boehringer Mannheim, Indianapolis, IN) for 30 min at room temperature. After four washes with 100 mM Tris-HCl (pH 7.5), 150 mM NaCl, and 0.05% Tween 20, the Life Technologies amplification system was applied for the color reaction according to the manufacturer’s recommendations. The absorbance at 490 nm was recorded using a SpectraMax 250 plate reader (Molecular Devices, Sunnyvale, CA).

The primers for the ligation reactions were as follows: H²⁶⁸ (5'-CCTGGAATTTTCAGTTTCCTC-3'); Y²⁶⁸ (5'-CCTGGAATTTTCAGTTTCCAT-3'); and common primer (5'-ATCCACTCTTACCAAATGTTG-3'). The modifications for the primers were 5'-biotin for H²⁶⁸- and Y²⁶⁸-specific primers and 5'-phosphate and 3'-digoxigenin for the common primer. The ligation reactions were as described for UGT2B4.

UGT2B15(D⁸⁵Y).
The UGT2B15(D⁸⁵Y) polymorphism consists of a G-to-T point mutation, resulting in an amino acid change from aspartic acid (D) to tyrosine (Y) at amino acid 85 (9) . Primers 5'-GTTACTTTAGCTCTGGAAGC-3' and 5'-AGAGCTTGTTACTGTAGTCAT-3' were used to amplify a 333-bp fragment of the UGT2B15 gene containing the mutation. The PCR reactions contained 10 mM Tris-HCl (pH 8.3), 50 mM KCl, 1.5 mM MgCl₂, 0.001% gelatin, 50 ng/µl BSA, 100 µM deoxynucleotide triphosphates, 100 nM amplification primers, 100 ng of genomic DNA, and 0.5 units of AmpliTaq DNA polymerase (Perkin-Elmer). The cycling conditions on a PTC-100 thermal cycler (MJ Research) were as follows: 94°C for 5 min, followed by 35 cycles of 94°C for 30 s, 60°C for 45 s, 72°C for 60 s and 1 cycle of 72°C for 5 min.

The ligation was performed as described above for UGT2B7. The ligation primers for UGT2B15 were D⁸⁵ (5'-TCCTACATCTTTAACTAAAAATG-3'); Y⁸⁵ (5'-TCCTACATCTTTAACTAAAAATT-3'); and common primer (5'-ATTTGGAAGATTCTCTTCTGAA-3'). The modifications for the primers were 5'-biotin for D⁸⁵- and Y⁸⁵-specific primers and 5'-phosphate and 3'-digoxigenin for the common primer.

Statistical Analysis
Statistical analyses were conducted using SAS software (Version 6.12 for Windows; SAS Institute Inc., Cary, NC). We measured differences between observed and expected UGT2B4(D⁴⁵⁸E), UGT2B7(H²⁶⁸Y), and UGT2B15(D⁸⁵Y) genotype frequencies using the ² test and compared genotype frequencies between individuals of Asian and Caucasian background using Fisher’s exact test.

	Results

Top Abstract Introduction Materials and Methods Results Discussion References

 
The 245 individuals (146 women and 99 men) who were genotyped for this project described their ethnic backgrounds as follows: 202 Caucasian, 32 Asian (including individuals of Indian origin), 4 Hispanic, 2 Pacific Islander, 2 African, 1 Alaskan Native, 1 Asian/Caucasian, and 1 Native American/Caucasian. Data are presented only for Caucasians and Asians because the small numbers of individuals in the other categories preclude statistical comparison among these ethnic groups.

The UGT2B4(D⁴⁵⁸E), UGT2B7(H²⁶⁸Y), and UGT2B15(D⁸⁵Y) allele and genotype frequencies are presented in Table 2 . We did not detect the presence of the UGT2B4(L^109,396,D⁴⁵⁸) allelic variant in any of the samples. The allele frequencies were significantly different (P < 0.02) between individuals of Caucasian and Asian descent for all three polymorphisms. Genotype frequencies for the UGT2B4(D⁴⁵⁸E), UGT2B7(H²⁶⁸Y), and UGT2B15(D⁸⁵Y) polymorphisms also differed significantly by ethnic group (P < 0.0001, P = 0.0002, and P = 0.02, respectively). All of the Asians were homozygous wild type (D⁴⁵⁸/D⁴⁵⁸) for UGT2B4. For UGT2B7, almost 60% of individuals of Asian background were H²⁶⁸/H²⁶⁸ and only 9% were Y²⁶⁸/Y²⁶⁸, whereas among the Caucasians only 22% were H²⁶⁸/H²⁶⁸ and 29% were Y²⁶⁸/Y²⁶⁸. Similarly, for UGT2B15, 47% of Asians were D⁸⁵/D⁸⁵ and 19% were Y⁸⁵/Y⁸⁵, whereas 22% of Caucasians were D⁸⁵/D⁸⁵ and 32% were Y⁸⁵/Y⁸⁵. Within the Asian and Caucasian samples, the genotype frequencies were in Hardy-Weinberg equilibrium.

	Discussion

Top Abstract Introduction Materials and Methods Results Discussion References

The UGT2B4(L^109,396,D⁴⁵⁸) variant allele appears to be very rare. Lévesque et al. (7) did not find expression of the UGT2B4(L^109,396,D⁴⁵⁸) transcript in any tissue samples tested, nor did they find the allele in 26 samples of genomic DNA. Similarly, in our 10-fold larger sample, we also did not find any individuals with this allele.

The extent to which the 2B polymorphisms may influence xenobiotic and endogenous steroid conjugation remains to be determined. In UGT2B4, substitution of E for D at 458 probably is a relatively minor amino acid modification, and stably expressed UGT2B4(D⁴⁵⁸) and UGT2B4(E⁴⁵⁸) in HK293 cells show similar substrate specificity (7) . In the case of UGT2B7(H²⁶⁸Y), H-to-Y constitutes a nonconservative amino acid change in the region of the substrate binding site. Consequently, Jin et al. (8) postulated that the polymorphism would probably affect substrate specificity. In addition, they reported that UGT2B7(Y²⁶⁸), but not (H²⁶⁸), conjugated menthol and androsterone. More recently, Cheng et al. (12) and Coffman et al. (23) reported that in the case of catechol estrogens, androsterone, opioids, and several xenobiotics, substrate glucuronidation efficiency did not differ between cells designed to express UGT2B7(H²⁶⁸) or (Y²⁶⁸).

The polymorphism in UGT2B15(D⁸⁵Y) does not appear to alter specificities among the substrates tested to date, but it does increase the V_max by 2-fold and may contribute to individual variability in glucuronidation observed with some drugs and other compounds (24) . Specifically, UGT2B15(Y⁸⁵) has a higher V_max than UGTB15(D⁸⁵) for 5-androstane-3,17ß-diol and dihydrotestosterone (9) . Given the high prevalence of the variant allele (Y⁸⁵; 50%) and the small differences in kinetics, Lévesque et al. (9) suggested that differences in steroid hormone metabolism are unlikely to be observed in vivo, but that this polymorphism may contribute to individual variability in xenobiotic glucuronidation. On that basis, the implications of carrying the Y⁸⁵ homozygous genotype are unclear; however, if the V_max is higher for the numerous phytochemicals that are metabolized by UGT2B15, one might postulate that these compounds would be cleared more rapidly and their potential chemopreventive effects would be reduced.

In conclusion, we have detected a high prevalence of the polymorphisms in UGT2B4(D⁴⁵⁸E), UGT2B7(H²⁶⁸Y), and UGT2B15(D⁸⁵Y) in a small, convenient sample of healthy individuals. In addition, we observed significant ethnic differences between Asians and Caucasians in the distribution of these polymorphisms. The relationship between UGT2B polymorphisms and cancer risk has not been explored; however, the role of UGT2Bs in the conjugation and excretion of steroid hormones and the international differences in risk of hormone-dependent cancers suggest that these enzymes may be important candidates for additional study. Whether the genotypic differences explain, in part, observed ethnic differences in steroid hormone profiles and drug metabolism remains to be determined. Our results suggest that further investigation of these polymorphisms in large, multiethnic cohorts is warranted.

	Footnotes

 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

¹ Supported by NCI Grant R01 CA70913 (to J. D. P.) and Fred Hutchinson Cancer Research Center.

² To whom requests for reprints should be addressed, at Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North, MP-900, Seattle, WA 98109-1024. Phone: (206) 667-6580; Fax: (206) 667-7850; E-mail: jlampe{at}fhcrc.org

³ The abbreviation used is: UGT, UDP-glucuronosyltransferase.

Received 7/19/99; revised 12/15/99; accepted 12/23/99.

	References

Top Abstract Introduction Materials and Methods Results Discussion References

 

1. Mackenzie P. I., Owens I. S., Burchell B., Bock K. W., Bairoch A., Bélanger A., Fournel-Gigleux S., Green M., Hum D. W., Iyanagi T., Lancet D., Louisot P., Magdalou J., Chowdhury J. R., Ritter J. K., Schachter H., Tephly T. R., Tipton K. F., Nebert D. W. The UDP glycosyltransferase gene superfamily: recommended nomenclature update based on evolutionary divergence. Pharmacogenetics, 7: 255-269, 1997.[Medline]
2. Mackenzie P. I., Mojarrabi B., Meech R., Hansen A. Steroid UDP glucuronosyltransferases: characterization and regulation. J. Endocrinol., 150: S79-S86, 1996.[Abstract]
3. Strassburg C. P., Manns M. P., Tukey R. H. Differential down-regulation of the UDP-glucuronosyltransferase 1A locus is an early event in human liver and biliary cancer. Cancer Res., 57: 2979-2985, 1997.[Abstract/Free Full Text]
4. Miners J. O., Mackenzie P. I. Drug glucuronidation in humans. Pharmacol. Ther., 51: 347-369, 1991.[Medline]
5. Patel M., Tang B. K., Grant D. M., Kalow W. Interindividual variability in the glucuronidation of (S) oxazepam contrasted with that of (R) oxazepam. Pharmacogenetics, 5: 287-297, 1995.[Medline]
6. Bosma P. J., Chowdhury J. R., Bakker C., Gantla S., de Boer N., Oostra B. A., Lindhout D., Tytgat G. N. J., Jansen P. L. M., Oude Elferink R. P. J., Chowdhury N. R. The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert’s syndrome. N. Engl. J. Med., 333: 1171-1175, 1995.[Abstract/Free Full Text]
7. Lévesque E., Beaulieu M., Hum D. W., Bélanger A. Characterization and substrate specificity of UGT2B4(E⁴⁵⁸): a UDP-glucuronosyltransferase encoded by a polymorphic gene. Pharmacogenetics, 9: 207-216, 1999.[Medline]
8. Jin C., Miners J. O., Lillywhite K. J., Mackenzie P. I. Complementary deoxyribonucleic acid cloning and expression of a human liver urine diphosphate-glucuronosyltransferase glucuronidating carboxylic acid-containing drugs. J. Pharmacol. Exp. Ther., 264: 475-479, 1993.[Abstract/Free Full Text]
9. Lévesque E., Beaulieu M., Green M. D., Tephly T. R., Bélanger A., Hum D. W. Isolation and characterization of UGT2B15(Y⁸⁵): a UDP-glucuronosyltransferase encoded by a polymorphic gene. Pharmacogenetics, 7: 317-325, 1997.[Medline]
10. Jin C., Miners J. O., Lillywhite K. J., Mackenzie P. I. cDNA cloning and expression of 2 new members of the human liver UDP-glucuronosyltransferase-2B subfamily. Biochem. Biophys. Res. Commun., 194: 496-503, 1993.[Medline]
11. Mackenzie P. I. Expression of chimeric cDNAs in cell culture defines a region of UDP-glucuronosyltransferase involved in substrate selection. J. Biol. Chem., 265: 3432-3435, 1990.[Abstract/Free Full Text]
12. Cheng Z., Rios G. R., King C. D., Coffman B. L., Green M. D., Mojarrabi B., Mackenzie P. I., Tephly T. R. Glucuronidation of catechol estrogens by expressed human UDP-glucuronosyltransferases (UGTs) 1A1, 1A3, and 2B7. Toxicol. Sci., 45: 52-57, 1998.[Abstract/Free Full Text]
13. Ritter J. K., Sheen Y. Y., Owens I. S. Cloning and expression of human liver UDP-glucuronyltransferase in COS-1 cells: 3,4-catechol estrogens and estriol as primary substrates. J. Biol. Chem., 265: 7900-7906, 1990.[Abstract/Free Full Text]
14. Jin C., Mackenzie P. I., Miners J. O. The regio- and stereo-selectivity of C19 and C21 hydroxysteroid glucuronidation by UGT2B7 and UGT2B11. Arch. Biochem. Biophys., 341: 207-211, 1997.[Medline]
15. Radominska-Pandya A., Little J. M., Pandya J. T., Tephly T. R., King C. D., Barone G. W., Raufman J.-P. UDP-glucuronosyltransferases in human intestinal mucosa. Biochim. Biophys. Acta, 1394: 199-208, 1998.[Medline]
16. King C. D., Rios G. R., Assouline J. A., Tephly T. R. Expression of UDP-glucuronosyltransferases (UGTs) 2B7 and 1A6 in the human brain and identification of 5-hydroxytryptamine as a substrate. Arch. Biochem. Biophys., 365: 156-162, 1999.[Medline]
17. Strassburg C. P., Strassburg A., Nguyen N., Li Q., Manns M. P., Tukey R. H. Regulation and function of family 1 and family 2 UDP-glucuronosyltransferase genes (UGT1A, UGT2B) in human oesophagus. Biochem. J., 338: 489-498, 1999.
18. Chen F., Ritter J. K., Wang M. G., Mcbride O. W., Lubet R. A., Owens I. S. Characterization of a cloned human dihydrotestosterone/androstanediol UDP-glucuronosyltransferase and its comparison to other steroid isoforms. Biochemistry, 32: 10648-10657, 1993.[Medline]
19. Green M., Oturu E. M., Tephly T. R. Stable expression of a human liver UDP-glucuronosyltransferase (UGT2B15) with activity toward steroid and xenobiotic substrates. Drug Metab. Dispos., 22: 799-805, 1994.[Abstract]
20. Strauss W. M. Preparation of genomic DNA from mammalian tissue Ausubel F. M. Bren R. Kingston R. E. Moore D. D. Seidman J. G. Smith J. A. Struhl K. eds. . Current Protocols in Molecular Biology, : 2.2.1-2.2.3, John Wiley & Sons, Inc. New York 1999.
21. Nickerson D. A., Kaiser R., Lappin S., Stewart J., Hood L., Landegren U. Automated DNA diagnostics using an ELISA-based oligonucleotide ligation assay. Proc. Natl. Acad. Sci. USA, 87: 8923-8927, 1990.[Abstract/Free Full Text]
22. Bigler J., Chen C., Potter J. D. Determination of human NAT2 acetylator genotype by oligonucleotide ligation assay. Biotechniques, 22: 682-684, 686, 688, 1997.[Medline]
23. Coffman B. L., King C. D., Rios G. R., Tephly T. R. The glucuronidation of opioids, other xenobiotics, and androgens by human UGT2B7Y(268) and UGT2B7H(268). Drug Metab Dispos., 26: 73-77, 1998.[Abstract/Free Full Text]
24. Bélanger A., Hum D. W., Beaulieu M., Lévesque E., Guillemette C., Tchernof A., Bélanger G., Turgeon D., Dubois S. Characterization and regulation of UDP-glucuronosyltransferases in steroid target tissues. J. Steroid Biochem. Mol. Biol., 65: 301-310, 1998.[Medline]

This article has been cited by other articles:

				C. Swanson, M. Lorentzon, L. Vandenput, F. Labrie, A. Rane, J. Jakobsson, S. Chouinard, A. Belanger, and C. Ohlsson Sex Steroid Levels and Cortical Bone Size in Young Men Are Associated with a Uridine Diphosphate Glucuronosyltransferase 2B7 Polymorphism (H268Y) J. Clin. Endocrinol. Metab., September 1, 2007; 92(9): 3697 - 3704. [Abstract] [Full Text] [PDF]

				O. Bernard, J. Tojcic, K. Journault, L. Perusse, and C. Guillemette Influence of Nonsynonymous Polymorphisms of UGT1A8 and UGT2B7 Metabolizing Enzymes on the Formation of Phenolic and Acyl Glucuronides of Mycophenolic Acid Drug Metab. Dispos., September 1, 2006; 34(9): 1539 - 1545. [Abstract] [Full Text] [PDF]

				J. R. Ross, J. Riley, C. Quigley, and K. I. Welsh Clinical Pharmacology and Pharmacotherapy of Opioid Switching in Cancer Patients Oncologist, July 1, 2006; 11(7): 765 - 773. [Abstract] [Full Text] [PDF]

				G. E. Kuehl, J. Bigler, J. D. Potter, and J. W. Lampe GLUCURONIDATION OF THE ASPIRIN METABOLITE SALICYLIC ACID BY EXPRESSED UDP-GLUCURONOSYLTRANSFERASES AND HUMAN LIVER MICROSOMES Drug Metab. Dispos., February 1, 2006; 34(2): 199 - 202. [Abstract] [Full Text] [PDF]

				J. Jakobsson, L. Ekstrom, N. Inotsume, M. Garle, M. Lorentzon, C. Ohlsson, H.-K. Roh, K. Carlstrom, and A. Rane Large Differences in Testosterone Excretion in Korean and Swedish Men Are Strongly Associated with a UDP-Glucuronosyl Transferase 2B17 Polymorphism J. Clin. Endocrinol. Metab., February 1, 2006; 91(2): 687 - 693. [Abstract] [Full Text] [PDF]

				G. E. Kuehl, J. W. Lampe, J. D. Potter, and J. Bigler GLUCURONIDATION OF NONSTEROIDAL ANTI-INFLAMMATORY DRUGS: IDENTIFYING THE ENZYMES RESPONSIBLE IN HUMAN LIVER MICROSOMES Drug Metab. Dispos., July 1, 2005; 33(7): 1027 - 1035. [Abstract] [Full Text] [PDF]

				M. Saeki, Y. Saito, H. Jinno, T. Tanaka-Kagawa, A. Ohno, S. Ozawa, K. Ueno, S. Kamakura, N. Kamatani, K. Komamura, et al. SINGLE NUCLEOTIDE POLYMORPHISMS AND HAPLOTYPE FREQUENCIES OF UGT2B4 AND UGT2B7 IN A JAPANESE POPULATION Drug Metab. Dispos., September 1, 2004; 32(9): 1048 - 1054. [Abstract] [Full Text] [PDF]

				M. H. Court, Q. Hao, S. Krishnaswamy, T. Bekaii-Saab, A. Al-Rohaimi, L. L. von Moltke, and D. J. Greenblatt UDP-Glucuronosyltransferase (UGT) 2B15 Pharmacogenetics: UGT2B15 D85Y Genotype and Gender Are Major Determinants of Oxazepam Glucuronidation by Human Liver J. Pharmacol. Exp. Ther., August 1, 2004; 310(2): 656 - 665. [Abstract] [Full Text] [PDF]

				P. G. Wells, P. I. Mackenzie, J. Roy Chowdhury, C. Guillemette, P. A. Gregory, Y. Ishii, A. J. Hansen, F. K. Kessler, P. M. Kim, N. Roy Chowdhury, et al. GLUCURONIDATION AND THE UDP-GLUCURONOSYLTRANSFERASES IN HEALTH AND DISEASE Drug Metab. Dispos., March 1, 2004; 32(3): 281 - 290. [Abstract] [Full Text] [PDF]

				C. Girard, O. Barbier, G. Veilleux, M. El-Alfy, and A. Belanger Human Uridine Diphosphate-Glucuronosyltransferase UGT2B7 Conjugates Mineralocorticoid and Glucocorticoid Metabolites Endocrinology, June 1, 2003; 144(6): 2659 - 2668. [Abstract] [Full Text] [PDF]

				J. Y. Zhang, J. Zhan, C. S. Cook, R. M. Ings, and A. P. Breau Involvement of Human UGT2B7 and 2B15 in Rofecoxib Metabolism Drug Metab. Dispos., May 1, 2003; 31(5): 652 - 658. [Abstract] [Full Text] [PDF]

				M. H. Court, S. X. Duan, C. Guillemette, K. Journault, S. Krishnaswamy, L. L. von Moltke, and D. J. Greenblatt Stereoselective Conjugation of Oxazepam by Human UDP-Glucuronosyltransferases (UGTs): S-Oxazepam Is Glucuronidated by UGT2B15, While R-Oxazepam Is Glucuronidated by UGT2B7 and UGT1A9 Drug Metab. Dispos., November 1, 2002; 30(11): 1257 - 1265. [Abstract] [Full Text] [PDF]

				A. Gsur, M. Preyer, G. Haidinger, G. Schatzl, S. Madersbacher, M. Marberger, C. Vutuc, and M. Micksche A Polymorphism in the UDP-Glucuronosyltransferase 2B15 Gene (D85Y) Is Not Associated with Prostate Cancer Risk Cancer Epidemiol. Biomarkers Prev., May 1, 2002; 11(5): 497 - 498. [Full Text] [PDF]

				R. Elsby, J. L. Maggs, J. Ashby, and B. K. Park Comparison of the Modulatory Effects of Human and Rat Liver Microsomal Metabolism on the Estrogenicity of Bisphenol A: Implications for Extrapolation to Humans J. Pharmacol. Exp. Ther., April 1, 2001; 297(1): 103 - 113. [Abstract] [Full Text]

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lampe, J. W. Articles by Potter, J. D. Search for Related Content PubMed PubMed Citation Articles by Lampe, J. W. Articles by Potter, J. D.